Viridian Therapeutics, Inc.
$19.06
The Read: VRDN's stock has historically fallen sharply when FDA delays or refusals disrupted expected approval timelines, rallied modestly on financial updates hitting targets, but then declined after positive trial data was overshadowed by dilutive public offerings.
Price
Overlays
Panel
VRDN
Hover to view data
No Data